Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Open accessThe DOI matches its Crossref record; 306 of the 306 references it cites were found in a registry or an index.
Abstract
Worldwide, nearly 40% of adults are overweight and 13% are obese. Health consequences of excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, and increased mortality. Treating obesity is challenging and calorie restriction often leads to rebound weight gain. Treatments such as bariatric surgery create hesitancy among patients due to their invasiveness. GLP-1 medications have revolutionized weight loss and can reduce body weight in obese patients by between 15% and 25% on average after about 1 year. Their mode of action is to mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism and satiety. However, GLP-1 drugs carry known risks and, since their use for weight loss is recent, may carry unforeseen risks as well. They carry a boxed warning for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) are fairly common while pancreatitis and intestinal obstruction are rarer. There may be a loss of lean body mass as well as premature facial aging. A significant disadvantage of using these medications is the high rate of weight regain when they are discontinued. Achieving success with pharmacologic treatment and then weaning to avoid future negative effects would be ideal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our results show pleiotropic anti-inflammatory and antioxidant effects that may mechanistically underlie the cardiovascular, hepatic, and renal protection consistently seen in large-scale cardiovascular outcome studies (45, 46), in addition to their well-established benefits on glycemic control and weight reduction (47, 48).”
From Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis (2026) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Even highly efficacious GLP-1 agonists face challenges, including variable response rates, gastrointestinal side effects, and weight regain after discontinuation.”
From The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities (2026) · cites this paper as [35]
In the citing paper
“Symptoms such as reduced appetite, early satiety, and nausea may limit dietary variety and protein intake, leading to muscle loss [63,64,65].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–306 of 306
GLP‐1 agonists and hair loss: a call for further investigation
Desai, D. D., Sikora, M., Nohria, A., Bordone, L. A., Caplan, A. S., Shapiro, J., & Sicco, K. I. L. (2024) · International Journal of Dermatology · doi:10.1111/ijd.17246 · Cited by 46 · cited 2×
“…Discontinue drug, standard treatment for pancreatitis [156] Alopecia Change to a different GLP-1 medication, topical hair loss treatments [174] “Ozempic face” Cosmetic procedures such as facelift, dermatologic fillers, autologous fat transfer [177,178] Sarcopenia Exercise (emphasize…”
Gabe, M. B. N., Breitschaft, A., Knop, F. K., Hansen, M. R., Kirkeby, K., Rathor, N., & Adrian, C. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15802 · Cited by 46 · cited 1×
“While there are available therapies for hyperphagia and hunger and, in fact, appetite reduction is a key effect of GLP-1 agonists, there are no significant available therapies that can address the decrease in energy expenditure [234].”
Garvey, W. T., Mahle, C. D., Bell, T., & Kushner, R. F. (2024) · Obesity Science & Practice · doi:10.1002/osp4.756 · Cited by 44 · cited 1×
“As the newer agents in the GLP class have become incredibly potent where users are losing an estimated 15-20% of body weight, with much of the weight loss occurring in the initial weeks of initiating the drug [175,176].”
Obesity, white adipose tissue and cancer
Solsona‐Vilarrasa, E., & Vousden, K. H. (2024) · FEBS Journal · doi:10.1111/febs.17312 · Cited by 44 · cited 1×
“Obesity also elevates the risk of developing some types of cancer including colorectal, esophageal, liver, and kidney malignancies [28–32].”
Wei, J., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.910256 · Cited by 43 · cited 2×
“This is generally a benign clinical finding with no associated arrhythmias from GLP-1 usage [186,187].”
Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature
Pavli, P., Triantafyllidou, O., Kapantais, E., Vlahos, N., & Valsamakis, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031909 · Cited by 43 · cited 1×
“Secondarily medically induced weight loss, particularly when totaling in excess of 5% of total body weight has demonstrated effectiveness in improving fertility [207].”
Carbohydrate Restriction-Induced Elevations in LDL-Cholesterol and Atherosclerosis
Budoff, M. J., Manubolu, V. S., Kinninger, A., Norwitz, N. G., Feldman, D., Wood, T. R., Fialkow, J. A., Cury, R. C., Feldman, T., & Nasir, K. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101109 · Cited by 43 · cited 1×
“Exceeding 6-12 months of use may have undesired effects by increasing LDL cholesterol and cardiovascular risk in some studies, but others have found no difference [50–53].”
Santos, L. B., Mizubuti, G. B., da Silva, L. M., Silveira, S. Q., Nersessian, R. S. F., Abib, A. D. C. V., Bellicieri, F. N., Lima, H. D. O., Ho, A. M.-H., dos Anjos, G. S., et al. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111668 · Cited by 43 · cited 1×
“Though more evidence is needed such guidance is useful to patients and clinicians at the present time [216,217].”
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43 · cited 1×
“The general trajectory of weight loss with initiation of GLP-1 therapy has been well-studied (Table 2) [218–220].”
Halpern, B., & Mancini, M. C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1247807 · Cited by 41 · cited 1×
“Anti-obesity medications such as Contrave (bupropion/naltrexone) or Qsymia (phentermine/topiramate) also appear to be effective for maintaining weight loss [63].”
Medical and Surgical Treatment of Obesity
Reid, T. J., & Körner, J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.03.002 · Cited by 40 · cited 1×
“Treating obesity has evolved in recent years, with various shifts in dietary, pharmacological, and surgical strategies available for the management of obesity [41].”
New insights in the mechanisms of weight‐loss maintenance: Summary from a Pennington symposium
Flanagan, E. W., Spann, R., Berry, S. E., Berthoud, H., Broyles, S., Foster, G. D., Krakoff, J., Loos, R. J. F., Lowe, M. R., Ostendorf, D. M., et al. (2023) · Obesity · doi:10.1002/oby.23905 · Cited by 40 · cited 1×
“Even more recently in 2022, a symposium was convened to discuss the state of the science of weight loss maintenance, known as the Pennington Biomedical Scientific Symposium [249].”
Weight Loss Programs: Why Do They Fail? A Multidimensional Approach for Obesity Management
Khattab, R. Y. (2024) · Current Nutrition Reports · doi:10.1007/s13668-024-00551-x · Cited by 40 · cited 1×
“Lifestyle interventions alone are not durable for most people [299,300].”
Jensen, T. L., Brønden, A., Karstoft, K., Sonne, D. P., & Christensen, M. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s419304 · Cited by 36 · cited 1×
“As the newer agents in the GLP class have become incredibly potent where users are losing an estimated 15-20% of body weight, with much of the weight loss occurring in the initial weeks of initiating the drug [175,176].”
Maslin, K., Alkutbe, R. B., Gilbert, J., Pinkney, J. H., & Shawe, J. (2024) · Clinical Obesity · doi:10.1111/cob.12690 · Cited by 34 · cited 1×
“Accidental human evidence has not been associated with any adverse outcomes, but overall data are scarce [205,206].”
Rochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., Itani, L., & El Ghoch, M. (2024) · Diseases · doi:10.3390/diseases12090204 · Cited by 34 · cited 2×
“Tirzepatide has demonstrated total lean mass loss as well, although additional studies are needed to determine the impact of this [134,182].”
Neve, K. L., & Isaacs, A. (2021) · Obesity Reviews · doi:10.1111/obr.13398 · Cited by 33 · cited 1×
“Processed foods are difficult to remove from the population’s food supply and public diets, due to their ubiquity as well as their low cost, convenience, and appealing taste [252,253].”
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 33 · cited 1×
“The contributing to Obesity is also strongly associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis, which is inflammation-driven [25–27].”
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Nicze, M., Dec, A., Borówka, M., Krzyżak, D., Bołdys, A., Bułdak, Ł., & Okopień, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158202 · Cited by 33 · cited 1×
“However, available studies are only seen in rodent studies, but the additive or synergistic effects of GLP-1 and GIP on hunger and satiety require further clinical research [285].”
Guo, H., Yang, J., Huang, J., Xu, L., Lv, Y., Wang, Y., Ren, J., Feng, Y., Zheng, Q., & Li, L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100162 · Cited by 32 · cited 1×
“…to nausea and vomiting, other GI-related side effects include diarrhea, constipation, dyspepsia, decreased appetite, and abdominal pain [158–160]. particularly be needed for ffl icted with sarcopenic obesity, a condition of a mismatch between It is estimated that around 80–90% of patients…”
Metabolic Adaptations to Weight Loss: A Brief Review
Martínez-Gómez, M. G., & Roberts, B. M. (2022) · Journal of Strength & Conditioning Research · doi:10.1519/jsc.0000000000003991 · Cited by 32 · cited 1×
“Hypometabolism, or the decrease of energy expenditure greater than what would be predicted, is known as metabolic adaptation [232].”
Silva, L. B., & Neto, M. G. (2022) · Minimally Invasive Therapy & Allied Technologies · doi:10.1080/13645706.2021.1874420 · Cited by 32 · cited 1×
“It is a temporary and minimally invasive therapy that reduces stomach capacity and results in decreased hunger and food intake [68,69].”
Zhou, J., Huang, W., Xie, Y., Shen, H., Liu, M., & Wu, X. (2024) · Endocrine · doi:10.1007/s12020-024-04112-8 · Cited by 32 · cited 1×
“Ocular GLP-1 therapy has two ophthalmological manifestations warranting discussion [191].”
Banded Versus Nonbanded Sleeve Gastrectomy: A Randomized Controlled Trial With 3 Years of Follow-up
Fink, J. M., Hetzenecker, A., Seifert, G. J., Runkel, M., Laessle, C., Fichtner‐Feigl, S., & Marjanović, G. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004174 · Cited by 31 · cited 1×
“Emerging evidence suggests that the sleeve procedure is associated with few reoperations, but significant regain of weight while the bypass procedure can lead to more durable weight loss and glycemic control [72,73].”
Masaki, T., Ozeki, Y., Yoshida, Y., Okamoto, M., Miyamoto, S., Gotoh, K., & Shibata, H. (2022) · Metabolites · doi:10.3390/metabo12020147 · Cited by 30 · cited 1×
“A growing number of trials have studied the beneficial impact of GLP-1 agonists on metabolic dysfunction associated with steatotic liver disease (MASLD), chronic kidney disease, as well as cardiovascular disease [121–124].”
Taking Orlistat: Predicting Weight Loss over 6 Months
Hollywood, A., & Ogden, J. (2011) · Journal of Obesity · doi:10.1155/2011/806896 · Cited by 28 · cited 1×
“By reducing absorption of fat via the intestine, it promotes weight loss [60].”
GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care
Manne‐Goehler, J., Teufel, F., & Venter, F. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.3579 · Cited by 27 · cited 1×
“It may be possible to maintain weight loss while tapering GLP-1 to a lower dosage or prolonging the time between doses [276,277].”
High risk and low incidence diseases: Bariatric surgery complications
Farooqi, S., Montrief, T., Koyfman, A., & Long, B. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.10.050 · Cited by 26
Ostendorf, D. M., Melanson, E. L., Caldwell, A. E., Creasy, S. A., Pan, Z., MacLean, P. S., Wyatt, H. R., Hill, J. O., & Catenacci, V. A. (2018) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy179 · Cited by 25 · cited 1×
“It is therefore rational to consider these processes as targets to prevent weight regain and achieve weight loss maintenance, although some studies show that energy expenditure is not uniformly disproportionately decreased in those sustaining weight loss long-term [233].”
A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data
Du, Y., Zhang, M., Wang, Z., Hu, M., Xie, D., Wang, X., Guo, Z., Zhu, J., Zhang, W., Luo, Z., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14229 · Cited by 25 · cited 1×
“Recent trials on the newer GLP-1 agents including tirzepatide and semaglutide specific to weight loss have not demonstrated increased rates of pancreatitis, although product labeling still instructs avoidance in patients with a history of pancreatitis [167–169].”
Central pre-proglucagon derived peptides: Opportunities for treatment of obesity
Larsen, P., Vrang, N., & Tang-Christensen, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454775 · Cited by 24 · cited 1×
“It is interesting to note that proglucagon and proglucagon-derived peptides (e.g., GLP-1, glucagon-like peptide-2, oxyntomodulin) are present in a small group of neurons in the nucleus tract solitarius within the brainstem and are another source of endogenous GLP-1 production [113,114].”
Kittner, S. L., Talbott, A. L., Vishneski, S. R., Narbaiza, J., & Shields, J. S. (2023) · JBJS Case Connector · doi:10.2106/jbjs.cc.23.00506 · Cited by 24 · cited 1×
“Early case reports called into question appropriate fasting times for pre-procedural and operative fasting due to retained gastric contents and risk of aspiration in patients taking GLP-1 medications and compounds [213,214].”
Ostendorf, D. M., Blankenship, J. M., Grau, L., Arbet, J., Mitchell, N. S., Creasy, S. A., Caldwell, A. E., Melanson, E. L., Phelan, S., Bessesen, D. H., et al. (2021) · Obesity Science & Practice · doi:10.1002/osp4.530 · Cited by 23 · cited 1×
“On the other hand, Ostendorf et al. found that high levels of physical activity including 200-300 min/week of at least moderate-intensity aerobic activity for upwards of 18 months supported weight loss maintenance [261].”
Chetty, A. K., Rafi, E., Bellini, N. J., Buchholz, N., & Isaacs, D. M. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.12.010 · Cited by 23 · cited 1×
“Despite the overall efficacy of the incretin-based treatments for weight loss, there is a lack of long-term controlled studies beyond about 4 years available [221,222].”
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Horváth, L., Mráz, M., Jude, E. B., & Haluzík, M. (2024) · Drugs · doi:10.1007/s40265-024-02029-0 · Cited by 22
Anti-atherosclerotic effect of incretin receptor agonists
Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., & Yang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463547 · Cited by 22 · cited 1×
“There are a number of proposed mechanisms including reduction of inflammation, improvement of endothelial and ventricular function, as well as decreasing platelet aggregation [128].”
Baker, D. E., Walley, K., & Levien, T. L. (2023) · Hospital Pharmacy · doi:10.1177/00185787221125724 · Cited by 21 · cited 1×
“Recent trials on the newer GLP-1 agents including tirzepatide and semaglutide specific to weight loss have not demonstrated increased rates of pancreatitis, although product labeling still instructs avoidance in patients with a history of pancreatitis [167–169].”
Kim, D. D., Hwang, J. H., & Fendrick, A. M. (2024) · Health Affairs Scholar · doi:10.1093/haschl/qxae055 · Cited by 21 · cited 1×
“The use of GLP-1 drugs as a weight loss tool is prevalent and effective, but it is preferable to find ways to keep the weight off without a lifetime of drug treatment and this is an area that needs attention [298].”
Aspiration risk with glucagon‐like peptide 1 ( GLP ‐1) agonists
Marroquin‐Harris, M., & Olesnicky, B. (2023) · Anaesthesia · doi:10.1111/anae.16099 · Cited by 20 · cited 1×
“Patients have also been reported to take “drug holidays” in which they pause the use of the drug intermittently for special occasions, but there is very little in the literature on this [278].”
Lin, Y., Wu, J., Lee, M.-C., Su, C.-Y., Toh, H. S., Chang, W., Chen, S.-Y., Kuo, F., Tang, H., & Liao, C. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae093 · Cited by 20 · cited 1×
“A meta-analysis from Lin et al. showed the benefit of GLP-1 drugs in peripheral artery disease and heart failure [129].”
Stoll, F., Kantowski, T., Laaser, J., Kloiber, U., Plitzko, G., Mann, O., Aberle, J., & Lautenbach, A. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.02.004 · Cited by 20 · cited 1×
“GLP-1 agonists are being explored as an adjunctive therapy to combine with bariatric surgery to avoid the weight regain that can occur post-surgery [81,82].”
Cengiz, A., Wu, C. C., & Lawley, S. D. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16229 · Cited by 20 · cited 1×
“It may be possible to maintain weight loss while tapering GLP-1 to a lower dosage or prolonging the time between doses [276,277].”
Boulmpou, A., Patoulias, D., Papadopoulos, C. E., Teperikidis, E., Doumas, M. N., & Vassilikos, V. P. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2087839 · Cited by 19 · cited 2×
“This is generally a benign clinical finding with no associated arrhythmias from GLP-1 usage [186,187].”
The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity
Grave, R. D. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s447582 · Cited by 19 · cited 1×
“The NCWR highlights variables associated with weight loss maintenance success for upwards of 10 years, although this study is with a motivated population of individuals [243,292].”
Mellbin, L., Bhatt, D. L., David, J., Ekström, K., Petrie, M. C., Rasmussen, S., & Vilsbøll, T. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae028 · Cited by 19
Marinho, T. D. S., Fabiano, M. M., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149225 · Cited by 19 · cited 1×
“The popularity of GLP-1 receptor analogs may have to do with their profound effects on the CNS. Early studies demonstrated the anorectic actions of GLP-1 on the hypothalamus [238,239].”
Akbari, M., Vali, M., Rezaei, S., Bazmi, S., Tabrizi, R., & Lankarani, K. B. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.08.023 · Cited by 19 · cited 1×
“For instance, high protein diet, Mediterranean-style diet, low carbohydrate diet, low-calorie diet, and low-fat diet are just several options [42,43].”
Li, J., Xie, J., Han, Y., Zhang, W., Wang, Y., & Jiang, Z. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0286 · Cited by 19 · cited 1×
“It was FDA-approved for weight loss in November 2023 [154].”
Papathanasiou, T., Strathe, A., Agersø, H., Lund, T. M., & Overgaard, R. V. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13985 · Cited by 18 · cited 1×
“Certainly, teaching patients to be mindful of their eating and to consume adequate protein can contribute to weight loss maintenance success and overall health [293].”
Verma, S., Emerson, S. S., Plutzky, J., Kahn, S. E., Stensen, S., Weeke, P., Musinga, D., Poirier, P., Lingvay, I., & Lincoff, A. M. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.008 · Cited by 18 · cited 1×
“SELECT also showed better cardiovascular outcomes in persons with obesity and without diabetes who had previously undergone coronary artery bypass graft surgery [126].”
Schmidt, P. H. S., Pasqualotto, E., dos Santos, H. V., de Souza, L. S. N., dos Santos, B. E., Chavez, M. P., Ferreira, R. O. M., Hohl, A., Ronsoni, M. F., & van de Sande-Lee, S. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.009 · Cited by 18 · cited 2×
“The question of whether the ratio between fat mass and lean body mass still unresolved [183 patients who are a muscle and fat mass.”
Low carbohydrate versus balanced carbohydrate diets for reducing weight and cardiovascular risk
Naude, C. E., Schoonees, A., Nguyen, K. A., Senekal, M., Young, T., Garner, P., Chaplin, M., & Volmink, J. A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013334 · Cited by 18
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17 · cited 1×
“The energy-dense nature of fat makes it an efficient means of storing excess energy intake and thus the body favors fat for keeping energy in reserve [91,92].”
Bays, H. E., Fitch, A., Francavilla Brown, C., Younglove, C., Christensen, S. M., & Alexander, L. C. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100122 · Cited by 16 · cited 1×
“Such a rapid increase in usage led to multiple drug shortages beginning in 2022 which continued through late 2024 [139].”
Burden of Disease and Cost of Illness of Overweight and Obesity in Portugal
Borges, M., Sampaio, F., da Costa, J. F. S., Freitas, P., Dias, C. M., Gaio, V., Conde, V., Figueira, D. C. M., Pinheiro, B., & Miguel, L. S. (2024) · Obesity Facts · doi:10.1159/000541781 · Cited by 16 · cited 1×
“Both cardio-vascular disease and cancer contribute to excess mortality associated with obesity [33,34].”
Block, C. E. M. D., Peleshok, J. C., Wilding, J. P. H., Kwan, A. Y. M., Rasouli, N., Maldonado, J. M., Wysham, C., Liu, M., Aleppo, G., & Benneyworth, B. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01660-0 · Cited by 16 · cited 1×
“The approval of tirzepatide, a novel long-acting dual incretin agonist of both GLP-1 and another incretin, GIP, continues to create excitement for the development of anti-obesity medications [279].”
Soini, S., Mustajoki, P., & Eriksson, J. G. (2018) · American Journal of Health Behavior · doi:10.5993/ajhb.42.1.8 · Cited by 15 · cited 1×
“Family encouragement and support have also been associated with successful weight loss management [271–273].”
Patel, M. L., Cleare, A. E., Smith, C. M., Rosas, L. G., & King, A. C. (2022) · JMIR Formative Research · doi:10.2196/42191 · Cited by 15 · cited 1×
“For health care practitioners, in-person sessions may be more successful than remote sessions, but both have value [246,274,275].”
Kripp, A. M., Feichter, A., & König, D. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1473747 · Cited by 15
Maan, M. S. A., Sohail, A. H., Sulaiman, S. A., Mansoor, L., Cohen, E. M., Adekolu, A. A., Abunnaja, S., Szoka, N. L., Tabone, L. E., Thakkar, S. J., et al. (2025) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2025.116242 · Cited by 15
Internal disinhibition predicts 5‐year weight regain in the National Weight Control Registry (NWCR)
Lillis, J., Thomas, J. G., Niemeier, H. M., & Wing, R. R. (2016) · Obesity Science & Practice · doi:10.1002/osp4.22 · Cited by 14 · cited 2×
“These successful subjects with weight loss maintenance reported high levels of physical activity, high levels of dietary restraint, low calorie, and fat intake, and low levels of overeating (loss of control of eating or disinhibition) [246].”
Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?
Singh, A. K., Kesavadev, J., & TIWASKAR, M. H. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0621 · Cited by 14 · cited 1×
“It is unclear whether those without type 2 diabetes using GLP-1 for weight loss are at the same risk [197,198].”
Gao, L., Yu, S., Cipriani, A., Wu, S., Huang, Y., Zhang, Z., Yang, J., Sun, Y., Yang, Z., Chai, S., et al. (2019) · Aging and Disease · doi:10.14336/ad.2019.0303 · Cited by 13 · cited 1×
“Headaches, dizziness, hypoglycemia, and injection site reactions have also been reported albeit to a much lesser degree [188,189].”
Borer, K. T. (2021) · Nutrients · doi:10.3390/nu13113812 · Cited by 13
Should Prediabetes be Treated Pharmacologically?
Davidson, M. B. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01449-7 · Cited by 13 · cited 1×
“Lifestyle interventions alone are not durable for most people [299,300].”
Long-term weight patterns and physical activity in gallstones
Kim, H. J., Kang, T., Kim, M. J., Swan, H., & Park, S. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-77218-8 · Cited by 13
Zhang, Y., Li, Z., & Hao, Y. (2025) · European journal of medical research · doi:10.1186/s40001-024-02241-4 · Cited by 13 · cited 1×
“Zhang et al. found that in persons with type 2 diabetes, GLP-1 drugs offered benefits whether or not the patients were also taking metformin [130].”
Salazar, M. A., Reyes, S. E. O., Estévez, A. M., Lobos, J. A. S., Aldecoa-Castillo, J. M. D., Aguas, J. C. C., Alaniz-Monreal, S., Rodríguez, J. A. N., & Sánchez, D. M. F. A. (2025) · Medicina · doi:10.3390/medicina61010088 · Cited by 13
Graham, G. V., McLaughlin, C. M., & Flatt, P. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14171 · Cited by 12 · cited 1×
“A synthetic version of exendin-4 was approved by the FDA in 2005 for glycemic control in type 2 diabetics [145,146].”
Fischer, M., Weimann, T. G., Oberänder, N., Schupitza, L., Hösel, J., & Weimann, A. (2022) · Annals of Nutrition and Metabolism · doi:10.1159/000526475 · Cited by 12 · cited 1×
“For health care practitioners, in-person sessions may be more successful than remote sessions, but both have value [246,274,275].”
Models Use Leptin and Calculus to Count Calories
Hall, K. D., & Heymsfield, S. B. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2008.12.006 · Cited by 11
Weight Loss Trajectories and Short-Term Prediction in an Online Weight Management Program
Zhou, B., Roberts, S. B., Das, S. K., & Naumova, E. N. (2024) · Nutrients · doi:10.3390/nu16081224 · Cited by 11 · cited 1×
“Studies are clearly needed to find ways to support withdrawal of pharmacotherapy without weight rebound using a multi-disciplinary approach which would likely involve behavioral change, nutritional guidance, structured physical activity, and perhaps peer support groups [301–305].”
Tian, C., Yang, Z. R., Zhao, S., Zhang, P., & Li, R. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.09.028 · Cited by 11 · cited 1×
“The FDA and studies from a cohort of Scandinavian patients concluded no association between GLP-1 use and suicidal ideation, self -harm, or new onset of depression [208–210].”
Goron, A. R., Connolly, C. T., Valdez‐Sinon, A. N., Hesson, A., Helou, C. M., & Kirschen, G. W. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206259 · Cited by 11 · cited 1×
“Early case reports called into question appropriate fasting times for pre-procedural and operative fasting due to retained gastric contents and risk of aspiration in patients taking GLP-1 medications and compounds [213,214].”
Does Incretin Agonism Have Sustainable Efficacy?
Janket, S., Chatanaka, M. K., Sohaei, D., Tamimi, F., Meurman, J. H., & Diamandis, E. P. (2024) · Cells · doi:10.3390/cells13221842 · Cited by 11 · cited 1×
“A multi-agonist approach is a likely road for the future of anti-obesity drug development involving novel receptors such as glucagon and amylin possibly with even more profound weight loss [286,287].”
Marwood, J., Brown, T. J., Kaiseler, M., Clare, K., Feeley, A. B., Blackshaw, J., & Ells, L. J. (2023) · Clinical Obesity · doi:10.1111/cob.12580 · Cited by 10 · cited 1×
“A supportive weight management team approach considers mood changes and how they can affect quality of life [269,270].”
Correlation between obstructive sleep apnea and weight-adjusted-waist index: a cross-sectional study
Zhang, M., Weng, X., Xu, J., & Xu, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1463184 · Cited by 10 · cited 1×
“Obesity is the strongest risk factor for obstructive sleep apnea [35].”
Zhu, J., Yan, Y., Qiu, X., Lin, S., & Wen, J. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01678-1 · Cited by 10 · cited 1×
“It is a temporary and minimally invasive therapy that reduces stomach capacity and results in decreased hunger and food intake [68,69].”
Falkenhain, K., Martin, C. K., Ravussin, É., & Redman, L. M. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01523-8 · Cited by 9 · cited 2×
“Most effective weight loss from a dietary standpoint is seen over 3 to 6 months, with at least one-third of patients regaining lost weight within the first year and the majority of patients regaining the weight after five years [224,225].”
Farah, A., Tatakis, A., Malshy, K., Mahajna, A., & Sayida, S. (2024) · Cureus · doi:10.7759/cureus.71919 · Cited by 8 · cited 1×
“Variations of Roux-en-Y gastric bypass limb lengths have shown potentially increased weight loss and metabolic benefit, but also, possible early and late significant complications [75–77].”
Kang, L., Chen, X., Qi, P., Ma, Z., Han, D., Zhang, X., & Shang, P. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-744 · Cited by 8
Long-Term Outcomes of Sleeve Gastrectomy Versus Gastric Bypass
Alaidaroos, O. Z. A., Jaber, A. A. A., Jaber, A., Alshehri, A., Alkehaimi, M. B., & Alsannat, O. A. (2024) · Cureus · doi:10.7759/cureus.72961 · Cited by 8 · cited 1×
“Emerging evidence suggests that the sleeve procedure is associated with few reoperations, but significant regain of weight while the bypass procedure can lead to more durable weight loss and glycemic control [72,73].”
Innovative Glucagon-based Therapies for Obesity
Belay, K. E., Jemal, R. H., & Tuyizere, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae197 · Cited by 8 · cited 1×
“A multi-agonist approach is a likely road for the future of anti-obesity drug development involving novel receptors such as glucagon and amylin possibly with even more profound weight loss [286,287].”
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss
Sforzo, G. A., Gordon, N. F., Peeke, P. M., & Moore, M. A. (2024) · American Journal of Lifestyle Medicine · doi:10.1177/15598276241302273 · Cited by 8
Incretin-Based Therapies: Facing the Realities of Benefits Versus Side Effects
Lebovitz, H. E. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0274 · Cited by 7 · cited 1×
“A common fi nding amongst all GLP-1 trials was that of increased heart rate attributed to a direct e ff ect on the pacemaker cells within the sinus node of the heart [185]. the development of pancreatitis [159].”
Choi, K.-E., Joung, C., Pahk, K. J., Kim, H., & Pahk, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1322326 · Cited by 7 · cited 2×
“Visceral adipose tissue is more metabolically active and associated with the pathophysiology seen in obesity such as insulin resistance [7].”
Ghoreishy, S. M., Noormohammadi, M., Zeraattalab-Motlagh, S., Shoaibinobarian, N., Rashedi, M. H., Movahed, S., Hemmati, A., Nazarian, A., Fernandez, M. L., & Shidfar, F. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae128 · Cited by 7 · cited 1×
“Other studies have found little to no impact of physical activity on maintaining weight loss [260].”
Kaya, E., Syn, W., & Manka, P. P. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001083 · Cited by 7 · cited 1×
“The contributing to Obesity is also strongly associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis, which is inflammation-driven [25–27].”
Hooker, A. R., Sagui-Henson, S. J., Daubenmier, J., Moran, P. J., Hartogensis, W., Acree, M., Kristeller, J., Epel, E. S., Mason, A. E., & Hecht, F. M. (2022) · Mindfulness · doi:10.1007/s12671-022-01951-2 · Cited by 6 · cited 1×
“Psychological well-being is an important aspect of both eating behaviors and weight loss [264,265].”
Sun, X., Yang, D., Li, Y., Shi, J., Zhang, X., & Yi, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171203 · Cited by 6 · cited 1×
“Amylin analogs such as cagrilintide are being explored for obesity treatment in concert with GLP-1 drugs [289].”
Bioactive compounds regulate appetite through the melanocortin system: a review
Niu, Y., Yu, W., Kou, X., Wu, S., Liu, M., Chen, C., Ji, J., Shao, Y., & Xue, Z. (2024) · Food & Function · doi:10.1039/d4fo04024d · Cited by 6 · cited 1×
“This includes the proopiomelanocortin and amphetamine-regulated transcript (POMC/CART) pathway, which promotes satiety and decreased hunger, often referred to as the anorectic pathway [116].”
Hung, J. C., Augustine, S. C., Cheng, K. T., Green, R. L., Hopkins, W. M., Laven, D. L., Nelson, B. R., Petry, N. A., Ponto, J. A., Quinton, T. M., et al. (2002) · Journal of the American Pharmaceutical Association (1996) · doi:10.1331/108658002764653568 · Cited by 5 · cited 1×
“Under section Section 503A of the FD&C Act compounding pharmacies were permitted to produce GLP-1 compounds to increase availability [140].”
Minderis, P., Fokin, A., Povilonis, T., Kvedaras, M., & Ratkevičius, A. (2023) · Nutrients · doi:10.3390/nu15224836 · Cited by 5 · cited 1×
“However, over the years, many studies have shown no differences in achieving weight loss from a variety of macronutrient approaches [45] and calorie reduction is likely the more successful approach for weight loss maintenance [250,251].”
Amylin analogs for the treatment of obesity without diabetes: present and future
Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2409403 · Cited by 5 · cited 1×
“Amylin and its analogs are gaining much interest [288].”
Glucagon-Like Peptide-1 Receptor Agonists in the Peri-Operative Period
Narasimhan, P. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0566 · Cited by 5
Hunger and the Obesity Epidemic: Old Insights Reaffirmed by New Medicines?
Taylor, R. (2023) · Annals of Internal Medicine · doi:10.7326/m23-0744 · Cited by 4 · cited 1×
“Cessation of these drugs to see if weight maintenance could be achieved was largely unsuccessful [241] (Table 3).”
Current State of Endoscopic Bariatric Therapies
Ying, L., Butensky, S. D., Ilang-Ying, Y., & Ghiassi, S. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.06.012 · Cited by 4 · cited 1×
“It can be used as a primary treatment for obesity, as an alternative for patients who do not qualify for bariatric surgery, or as a bridge to surgery [70].”
Petrovic, A., Jovičić, S. Ž., Dodevska, M. S., Djordjevic, B. I., Milinković, N., & Ivanović, N. (2024) · Nutrients · doi:10.3390/nu16203453 · Cited by 4 · cited 1×
“Energy balance is dependent on nutrient intake and subsequent nutrient oxidation rates [89,90].”
Obesity: A Profoundly Under Recognized Chronic Disease; And Its Impacts on Cardiovascular Disease.
Asif, M. (2024) · PubMed · Cited by 3
Katzmarzyk, P. T., Mire, E. F., Horswell, R. L., Chu, S. T., Zhang, D., Martin, C. K., Newton, R. L., Apolzan, J. W., Price‐Haywood, E. G., Fort, D. G., et al. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70017 · Cited by 3
Corrigendum: Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons
Humphrey, C. D., & Lawrence, A. C. (2023) · Facial Plastic Surgery · doi:10.1055/s-0044-1779676 · Cited by 3
Lau, R. G., Stevenson, M., Tirumalasetty, M. B., Lee, J., Hall, C. E., Miao, Q., BRATHWAITE, C. E. M., & Ragolia, L. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07578-7 · Cited by 2 · cited 1×
“Variations of Roux-en-Y gastric bypass limb lengths have shown potentially increased weight loss and metabolic benefit, but also, possible early and late significant complications [75–77].”
Self-citationGhnaim, A., Midlej, K., Zohud, O., Karram, S., Schäefer, A. S., Houri‐Haddad, Y., Lone, I. M., & Iraqi, F. A. (2024) · Cells · doi:10.3390/cells13211805 · Cited by 2 · cited 1×
“Obesity also elevates the risk of developing some types of cancer including colorectal, esophageal, liver, and kidney malignancies [28–32].”
Preliminary Review Finds No Link Between GLP-1 Receptor Agonists and Suicidality
Aschenbrenner, D. S. (2024) · AJN American Journal of Nursing · doi:10.1097/01.naj.0001016352.54091.a1 · Cited by 1 · cited 1×
“The FDA and studies from a cohort of Scandinavian patients concluded no association between GLP-1 use and suicidal ideation, self -harm, or new onset of depression [208–210].”
Ghnaim, A., Midlej, K., Zohud, O., et al. (2024) · Preprints.org · doi:10.20944/preprints202409.1094.v1 · Cited by 1
Perioperative Rhabdomyolysis in Obese Individuals Undergoing Bariatric Surgery: Current Status
Duarte-Medrano, G. A., Nuño‐Lámbarri, N., Palacios, M. M., Domínguez‐Cherit, G., Dominguez-Franco, A., Via, L. L., Paternò, D. S., & Sorbello, M. (2024) · Healthcare · doi:10.3390/healthcare12202029 · Cited by 1 · cited 1×
“However, the overall weight loss is still significant, and surgical weight loss is ultimately a personal choice for patients as it does carry risks [295–297].”
Cited by
Uti, D. E., Omang, W. A., Alum, E. U., Ugwu, O. P.-C., Wokoma, M. A., Oplekwu, I. R., Atangwho, I. J., & Egbung, G. E. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s529250 · Cited by 31
Sabatella, L., Ortega, P., Valentí, V., Rotellar, F., Pagola, A. U., Ahmed, A., Purkayastha, S., Tuero, C., Blanco, N., & Landecho, M. F. (2025) · Obesity · doi:10.1002/oby.70100 · Cited by 32
“This phenomenon has been clearly demonstrated in recent extension studies and real-world cohorts, underscoring the need for either continuous therapy or adjunctive strategies to sustain outcomes [46–48].”
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101708 · Cited by 28
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Metadata
- Authors
- Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J.
- Affiliations
- NYU Grossman Long Island School of Medicine (US)
- Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA
- Corresponding author
- Reiss, Allison B.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2025-03-13
- Volume
- 15
- Issue
- 3
- Pages
- 408
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC11940170
- OpenAlex
- W4408387882
- Semantic Scholar
- afb045c76cb862647622228026132eedba8d8b95
- Cited by
- 58
- References
- 304
- Citations by year
- 2026: 41 · 2025: 17
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- GLP-1 receptor agonists, obesity, weight loss, weight regain, drug discontinuation, satiety, multiple endocrine neoplasia type 2, gastrointestinal adverse effects, pancreatitis, intestinal obstruction, lean mass loss, facial aging
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.